FDA
-
-
-
-
-
-
-
Edgewise reports sevasemten stabilized function in Becker dystrophy study
-
-
-
-
-
-
-
Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
-
-
-
-
-
-
-
RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
-
-
-
-
-
-
-
Stifel Reiterates Hold Rating on Edgewise Therapeutics (EWTX)
-
-
-
-
-
-
-
Piper Sandler: 'We Remain Bullish on Edgewise Therapeutics (EWTX) and See Compelling Buying Opportunity'
-
-
-
-
-
-
-
Edgewise Therapeutics Inc. (EWTX) Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
-
-
-
-
-
-
-
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
-
323,293 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

